S
Shinji Kasai
Researcher at National Institutes of Health
Publications - 109
Citations - 3807
Shinji Kasai is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Gene & Knockdown resistance. The author has an hindex of 33, co-authored 92 publications receiving 3209 citations. Previous affiliations of Shinji Kasai include University of Tsukuba & Cornell University.
Papers
More filters
Journal ArticleDOI
Faunal and genetic studies of mosquitoes on Sado Island, Niigata Prefecture, Japan
TL;DR: In this paper , the current mosquito fauna on Sado Island was investigated by conducting surveillance in the Oosado mountainous area and the Kuninaka plain area from July 30 to August 3, 2019.
Journal ArticleDOI
FGFR1 tyrosine kinase domain duplication in infantile soft tissue spindle cell tumor.
Koshi Akahane,Shinji Kasai,Atsushi Watanabe,Keiko Kagami,Chiaki Komatsu,Minori Tamai,Kumiko Goi,Naoki Oishi,S. Yoshida,Chitose Ogawa,Eisuke Kobayashi,Takeshi Inukai +11 more
TL;DR: In this article , the authors present a method for the extraction of supporting information from the supporting information supplied by the authors of the article, which can be used to improve the performance of the analysis.
Journal ArticleDOI
Decreased incidence of acute immune thrombocytopenia in children during the COVID-19 pandemic
Daisuke Harama,Kumiko Goi,Kinuko Saito,Shinpei Somazu,Yoshiyuki Furuichi,Kazuya Takahashi,Hiroko Oshiro,Makoto Nakamura,Emi Sawanobori,Kazumasa Sato,Makoto Tsuruta,Yasushi Murakami,Tamao Shinohara,Atsushi Nemoto,Shinji Kasai,Minori Tamai,Atsushi Watanabe,Koshi Akahane,Satoru Kojika,Kanji Sugita,Takeshi Inukai +20 more
Journal ArticleDOI
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system
T. T. T. Nguyen,Minori Tamai,Daisuke Harama,Keiko Kagami,Shinji Kasai,Atsushi Watanabe,Koshi Akahane,Kumiko Goi,Takeshi Inukai +8 more
TL;DR: This authentic human model is helpful for developing new therapeutic strategies overcoming TKI resistance in Ph+ ALL due to T315I mutation, and the CRISPR/Cas9 system is appropriate for establishing a human model of Ph-lymphoid leukemia.